Introduction {#Sec1}
============

Lateral epicondylitis is the most commonly diagnosed condition of the elbow \[[@CR21]\], with a prevalence of 1--3 % in the general population \[[@CR34]\]. It affects men and women equally, mainly in the age range of 35−55 years \[[@CR2], [@CR28]\]. In most cases of lateral epicondylitis, no obvious underlying etiology can be identified \[[@CR25]\]. However, any activity that involves overuse of the wrist extensor or supinator muscles may be incriminating. The most commonly affected muscle is the extensor carpi radialis brevis (ECRB), as originally described by Cyriax \[[@CR2]\]. The pathology of lateral epicondylitis was previously considered to be from tendinitis, arising as inflammation of the tendon \[[@CR18]\]. Histopathologically, it has been shown to have a paucity of inflammatory cells such as macrophages and neutrophils \[[@CR7], [@CR11]\]. The condition is therefore considered to be a form of tendinosis, which is defined as a degenerative process \[[@CR2]\]. The treatment of lateral epicondylitis includes rest, nonsteroidal anti-inflammatory medication, bracing, physical therapy, extracorporeal shock wave therapy and botulinum toxin injection. Injection of corticosteroids (once the gold standard but now considered controversial), whole blood and platelet-rich plasma (PRP), and various types of surgical procedures have also been recommended \[[@CR4], [@CR8], [@CR17], [@CR27], [@CR29], [@CR35]\]. Injection with corticosteroids has been used since the 1950s and has been the treatment of choice for many years. However, several studies have shown no long-term beneficial effect; several alternative biologic injection therapies have therefore become available. Complex growth factor preparations, derived from the patients' own (autologous) blood, are used to drive the body's own tissue-healing mechanisms in the hope of stimulating rapid healing mechanisms \[[@CR5]\]. Two different preparations that are most described in the literature are autologous whole blood (AB) and platelet-rich plasma (PRP) injection \[[@CR5], [@CR10], [@CR12], [@CR14], [@CR19], [@CR21], [@CR23], [@CR24], [@CR26], [@CR33]\]. There have been several randomized controlled trials (RCTs) that have compared AB with PRP injection \[[@CR5], [@CR23], [@CR24], [@CR33]\], AB with steroid injection\[[@CR12], [@CR26]\] and PRP with steroid injection \[[@CR10], [@CR14], [@CR19], [@CR21]\]. However, results as to whether PRP, AB or corticosteroids is more beneficial are still unclear. Previous systematic reviews by Krogh et al. \[[@CR13]\] including 17 studies have shown eight different injection therapies reported by network meta-analysis. The results showed that AB, PRP and corticosteroids were more efficacious than placebo \[estimated by standardized mean difference (SMD)\]; however, there were no reports comparing the efficacy of PRP versus AB, PRP versus corticosteroids and AB versus corticosteroids. Ahmad et al. \[[@CR1]\] showed that PRP was more efficacious than blood injection in terms of non-response rate and conversion to surgery rates as well as pain visual analog score (VAS), and that PRP was more efficacious than corticosteroid injections in terms of pain and Disabilities of the Arm, Shoulder and Hand (DASH) score in only one of three studies, but two other studies showed no clinically significant difference. However, these meta-analyses included too few studies for pooling of the outcomes, utilized standardized mean difference, and lacked proper methodological quality required for performing a network meta-analysis. Neither heterogeneity nor sources of heterogeneity (age, sex, disease duration, preparation of the intervention and time to assess the outcome) were assessed. Moreover, other RCTs \[[@CR23], [@CR24], [@CR26]\] have been published since this study was done. Therefore, a systematic review was conducted with a network meta-analysis of RCTs at multiple follow-up times with the aim of comparing relevant clinical outcomes \[visual analog score, DASH score, Patient-Related Tennis Elbow Evaluation (PRTEE) score, adverse effects and non-response rates\] between AB, PRP and corticosteroids.

Materials and methods {#Sec2}
=====================

Search strategy {#Sec3}
---------------

The Medline and Scopus databases were used to identify relevant studies published in English from the date of inception to January 18, 2015. The PubMed and Scopus search engines were used to locate studies using the following search terms: 'lateral epicondylitis' and 'platelet-rich plasma' and 'clinical trial'. Relevant studies from the reference lists of identified studies and previous systematic reviews were also explored.

Selection of studies {#Sec4}
--------------------

Identified studies were selected by one author (J.K.) and randomly checked by A.A. Their titles and abstracts were initially screened; full papers were then retrieved if a decision could not be made from the abstracts. The reasons for ineligibility or exclusion of studies were recorded and described (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Flow-chart of study selection

Inclusion criteria {#Sec5}
------------------

Randomized controlled trials or quasi-experimental designs comparing clinical outcomes between treatments in lateral epicondylitis patients were eligible if they met the following criteria:compared clinical outcomes between PRP, AB and corticosteroid injectioncompared at least one of the following outcomes: visual analog score, DASH score, PRTEE score, pressure pain threshold (PPT), adverse effects and non-response rateshad sufficient data to extract and pool, namely reported mean, standard deviation (SD), and numbers of subjects according to treatments for continuous outcomes; number of patients according to treatment for dichotomous outcomes

Data extraction {#Sec6}
---------------

Two reviewers (J.K. and A.A.) independently performed data extraction using standardized data extraction forms. General characteristics of the subjects (e.g., mean age, gender, dominant side, duration of disease, pain score, disabilities scores and PPT at baseline) were extracted. The number of subjects, mean and SD of continuous outcomes, namely pain by VAS, DASH score, PRTEE score and PPT between groups, were extracted. Cross-tabulated frequencies between treatment and adverse effects were also extracted. Any disagreements were resolved by discussion and consensus with a third party (S.L.).

Risk of bias assessment {#Sec7}
-----------------------

Two authors (J.K. and T.A.) independently assessed the risk of bias for each study. Six study quality domains were considered, namely sequence generation, allocation concealment, blinding (participant, personnel, and outcome assessors), incomplete outcome data, selective outcome reporting, and other sources of bias \[[@CR15]\]. Disagreements between two authors were resolved by consensus and discussion with a third party (A.T.).

Outcomes {#Sec8}
--------

The outcomes of interest were pain VAS, DASH score, PRTEE score, complications and non-response rates. Methods of measurements of these outcomes were used according to the original studies. Briefly, this includes the VAS pain scale of 0--10, the DASH score which consists of 30 items with total scores ranging from 0 to 100, the PRTEE which consists of pain disability and functional disability with a total score ranging from 0 to 100, and pressure pain threshold (PPT) which was assessed by an algometer with scale units in kg/cm^2^. Postoperative adverse effects (skin reaction and local injection site pain) and non-response rates were considered.

Statistical analysis {#Sec9}
--------------------

Direct comparisons of continuous outcomes measured at the end of each study between PRP, AB and corticosteroid injection were pooled using an unstandardized mean difference (UMD). Heterogeneity of the mean difference across studies was checked using the *Q*-statistic and the degree of heterogeneity was quantified using the *I*^2^ statistic. If heterogeneity was present as determined by a statistically significant *Q*-statistic or by *I*^2^ \> 25 %, the UMD was estimated using a random effects model; otherwise a fixed effects model was applied.

For dichotomous outcomes, a relative risk (RR) of adverse effect of treatment comparisons at the end of each study was estimated and pooled. Heterogeneity was assessed using the previous method. If heterogeneity was present, the Dersimonian and Laird method \[[@CR3]\] was applied for pooling. If not, the fixed effects model by inverse variance method was applied. Meta-regression was applied to explore the source of heterogeneity (e.g., mean age, percentage of females, duration of disease, dominant hand side and follow-up time) if data was available. Publication bias was assessed using contour-enhanced funnel plots \[[@CR20], [@CR22]\] and Egger tests \[[@CR9]\].

For indirect comparisons, network meta-analyses were applied to assess all possible effects of treatment if summary data was available for pooling \[[@CR16], [@CR30], [@CR31]\]. A linear regression model, weighted by inverse variance, was applied to assess the treatment effects for continuous outcomes. For postoperative complications, a mixed-effect Poisson regression was applied to assess treatment effects \[[@CR16]\]. Summary data was expanded to individual patient data using the "expand" command in STATA. Treatment was considered as a fixed effect whereas the study variable was considered as a random effect in a mixed-effect model. The pooled RR and its 95 % confidence intervals (CIs) were estimated by exponential coefficients of treatments. All analyses were performed using STATA version 13.0 \[[@CR32]\]. *P* \< 0.05 was considered statistically significant, except for the test of heterogeneity where *P* \< 0.10 was used.

Results {#Sec10}
=======

Sixteen and 373 studies from Medline and Scopus were identified, respectively; 15 studies were duplicates, leaving 374 studies for review of titles and abstracts. Of these, nine studies \[[@CR5], [@CR12], [@CR14], [@CR19], [@CR21], [@CR23], [@CR24], [@CR26], [@CR33]\] plus one study \[[@CR6]\] identified from reference lists were reviewed, leaving a total of ten studies for data extraction. Characteristics of the 10 studies \[[@CR5], [@CR6], [@CR12], [@CR14], [@CR19], [@CR21], [@CR23], [@CR24], [@CR26], [@CR33]\] are given in Table [1](#Tab1){ref-type="table"}. Of seven PRP studies \[[@CR5], [@CR14], [@CR19], [@CR21], [@CR23], [@CR24], [@CR33]\], the comparators included AB in four studies \[[@CR5], [@CR23], [@CR24], [@CR33]\], and steroids in three studies \[[@CR14], [@CR19], [@CR21]\]. All three studies regarding AB were in comparison with steroids. Most studies \[[@CR5], [@CR6], [@CR14], [@CR21], [@CR23], [@CR26], [@CR33]\] assessed outcomes at more than 2 months; only three studies \[[@CR12], [@CR19], [@CR24]\] assessed outcomes at 1.5--2 months. Mean age, dominant side, duration of disease and VAS before treatment varied from 34 to 50 years, 57 to 85 %, 5 to 18 months and 5.5 to 7.6, respectively. The percentage of males ranged from 18 to 57 %. Various outcomes were compared between treatment groups (Fig. [1](#Fig1){ref-type="fig"}).Table 1Characteristics of included studiesReferencesYearsJournalInterventionComparatorFollow-up (months)Preparation of interventionAge (years)Sex (male %)Dominant side (%)Duration (months)VAS (0--10) before treatmentOutcomeKazemi et al. \[[@CR12]\]2010AJPMRABSteroid2Mixed blood with 1 ml of 2 % lidocaine47.11860--6.60VAS, DASH, PPT, adverse effectPeerboom et al. \[[@CR21]\]2010AMJPRPSteroid12The GPS III system47.14863--6.80VAS, DASH, adverse effectThanasas et al. \[[@CR33]\]2011AMJPRPAB6The GPS III system36.325865.16.05VAS, adverse effectDojode \[[@CR6]\]2012BJRABSteroid6Mixed blood with 1 ml of 0.5 % bupivacaine42.542858.67.6VAS, adverse effectOmar et al. \[[@CR19]\]2012Egypt RheumatologistPRPSteroid1.5Other system37.537601.88.40VAS, DASHSingh et al. \[[@CR26]\]2013J Health Allied SciABSteroid3Mixed blood with 1 ml of 2 % lidocaine34.1475718.1--PRTEEKrogh et al. \[[@CR14]\]2013AMJPRPSteroid3The Recover GPS II system45.85080--5.55PRTEE, adverse effectCreaney et al. \[[@CR5]\]2014BJSMPRPAB6Other system50.156.5------PRTEERaeissadat et al. \[[@CR23]\]2014BMC Sports SciencePRPAB12The Rooyagen kit43.52367--6.95VAS, PPTRaeissadat et al. \[[@CR24]\]2014Pain Research and TreatmentPRPAB2The Rooyagen kit46.34065--7.00VAS, PPT*AB* autologous blood injection, *Steroid* corticosteroid, *PRP* platelet-rich plasma, *VAS* visual analog score, *DASH* Disabilities of the Arm Shoulder and Hand, *PRTEE* Patient-Rated Tennis Elbow Evaluation, *PPT* pressure pain threshold

Risk of bias in included studies {#Sec11}
--------------------------------

The risk of bias assessment is described in Table [2](#Tab2){ref-type="table"}.Table 2Risk of bias assessmentReferencesAdequate sequence generationAdequate allocation concealmentBlindingAddress incomplete outcome dataSelective outcome reportFree of other biasDescription of other biasKazemi et al. \[[@CR12]\]YNYNYNDid not mention to ITTPeerboom et al. \[[@CR21]\]YYYYYY--Thanasas et al. \[[@CR33]\]YNYYYY--Dojode \[[@CR6]\]UNNYYY--Omar et al. \[[@CR19]\]UNNNYNPer protocol analysisSingh et al. \[[@CR26]\]UNNNYNPer protocol analysisKrogh et al. \[[@CR14]\]YYYYYY--Creaney et al. \[[@CR5]\]UYYYYY--Raeissadat et al. \[[@CR23]\]YNYNYNPer protocol analysisRaeissadat et al. \[[@CR24]\]YNNNYNPer protocol analysis

Direct comparisons {#Sec12}
------------------

Data for direct comparisons of all treatments and outcomes measured at the end of each study are given in Table [1](#Tab1){ref-type="table"}. Pooling according to outcomes was performed if there were at least two studies for each comparison, as clearly described below. There was no evidence of publication bias by Egger's test for both pooled effects of all outcomes from direct comparison.

### Visual analog score {#Sec13}

In seven studies \[[@CR6], [@CR12], [@CR19], [@CR21], [@CR23], [@CR24], [@CR33]\], the UMD of −1.7 (95 % CI −2.6, −0.8) and −2.5 (95 % CI −3.5, −1.5) showed that there was significantly lower VAS for PRP and AB, respectively, than for steroids (Table [3](#Tab3){ref-type="table"}). The UMD was homogeneous (*I*^2^ = 0) with a value of −1.1 (95 % CI −1.3, −0.8), showing that VAS was significant lower for PRP than AB.Table 3Summarized results of direct comparisons according to type of interventionsClinical outcomesNo. of studies*I* ^2^No. of subjectsUMD (95 % CI)VAS PRP vs. AB3072 vs. 72−1.1 (−1.3, −0.8)\* PRP vs. steroid277.466 vs. 64−1.7 (−2.6, −0.8)\* AB vs. steroid2060 vs. 60−2.5 (−3.5, −1.5)\*DASH score PRP vs. steroid291.696 vs. 94−16.3 (−22.3, −10.4)\* AB vs. steroid1--30 vs. 30−25.5 (−33.8, −17.2)\*PRTEE score PRP vs. AB1--80 vs 70−11.0 (−18.3, −3.7)\* PRP vs. steroid1--20 vs. 20−7.3 (−13.8, −0.9)\* AB vs. steroid1--30 vs. 30−5.3 (−9.1, −1.6)\*PPT PRP vs. AB26858 vs. 582.5 (−1.5, 6.5) AB vs. steroid1--30 vs. 309.9 (5.6, 14.2)\*Adverse effectsNo. of studies*I* ^2^No. of subjectsRR (95 % CI) PRP vs. AB1--14 vs.140.44 (0.17, 1.11) PRP vs. steroid2071 vs. 691.00 (0.31, 3.24) AB vs. steroid2060 vs. 601.78 (1.00, 3.17)\*Non-response rateNo. of studies*I* ^2^No. of subjectsRR (95 % CI) PRP vs. steroid1--51 vs. 491.23 (1.01, 1.49)\**PRP* platelet-rich plasma, *AB* autologous blood, *Steroid* corticosteroid, *VAS* visual analog score, *DASH* Disabilities of the Arm Shoulder and Hand, *PRTEE* Patient-Rated Tennis Elbow Evaluation, *PPT* pressure pain threshold, *I* ^2^ degree of heterogeneity, *UMD* unstandardized mean differences, *CI* confidence interval, *RR* relative risk**\*** Statistically significant difference (*P* \< 0.05)

### Disabilities of the Arm Shoulder and Hand score {#Sec14}

In three studies \[[@CR12], [@CR19], [@CR21]\], the UMD of −16.3 (95 % CI −22.3, −10.4) and −25.5 (95 % CI −33.8, −17.2) showed that there was a significantly lower DASH score for PRP and AB, respectively, than for steroids (Table [3](#Tab3){ref-type="table"}).

### Patient-Related Tennis Elbow Evaluation score {#Sec15}

In three studies \[[@CR5], [@CR14], [@CR26]\], the UMD of −7.3 (95 % CI −13.8, −0.9) and −5.3 (95 % CI −9.1, −1.6) showed that there was a significantly lower PRTEE score for PRP and AB, respectively, than for steroids (Table [3](#Tab3){ref-type="table"}). The UMD of −11.0 (95 % CI −18.3, −3.7) showing that the PRTEE score was significant lower for PRP than AB.

### Pressure pain threshold {#Sec16}

In three studies \[[@CR12], [@CR23], [@CR24]\], the UMD of 9.9 (95 % CI 5.6, 14.2) showed that there was a significantly higher PPT score for AB than steroids (Table [3](#Tab3){ref-type="table"}). The UMD of 2.5 (95 % CI −1.5, 6.5) showing that PPT was higher for PRP than AB, but this was not significant.

### Adverse effects (local pain and skin reaction) and non-response rates {#Sec17}

In five studies \[[@CR6], [@CR12], [@CR14], [@CR21], [@CR33]\], the pooled RR was 1.78 (95 % CI 1.00, 3.17), which showed a significantly higher risk of complications after AB injection when compared with steroids, and no heterogeneity (*I*^2^ = 0) was present (Table [3](#Tab3){ref-type="table"}). Compared with PRP, the pooled RR for AB and steroids had no statistically significant difference. Only one study \[[@CR21]\] reported non-response rates. The pooled RR was 1.23 (95 % CI 1.01, 1.49), which showed a significantly higher risk of non-response after PRP injection when compared with steroid injection.

Network meta-analysis {#Sec18}
---------------------

### Visual analog score {#Sec19}

Seven studies \[[@CR6], [@CR12], [@CR19], [@CR21], [@CR23], [@CR24], [@CR33]\] were included in the network meta-analysis. After being adjusted by time, the regression analysis suggested that for assessment within 2 months, the mean differences in VAS for PRP and AB showed that the VAS was lower than for steroid injection, but these were not significantly different (as seen in Table [4](#Tab4){ref-type="table"}; Fig. [2](#Fig2){ref-type="fig"}a). For assessment at the last follow-up, the mean difference in VAS for PRP and AB injection was lower, with statistical significance, than for steroid injection.Table 4Comparisons of treatment effects: a network meta-analysisTreatmentWithin 2 monthsAt last follow-up*N*Mean95 % CI*P* value*N*Mean95 % CI*P* valueVAS PRP1533.642.84, 4.45\<0.001\*1682.271.51, 3.02\<0.001\* AB1322.992.19, 3.80\<0.001\*1322.902.09, 3.70\<0.001\* Steroid794.183.04, 5.33,\<0.001\*944.293.31, 5.27\<0.001\*TreatmentWithin 2 monthsAt last follow-up*N*Mean difference95 % CI*P* value*N*Mean difference95 % CI*P* valueVAS PRP vs. steroid--−0.54−1.76, 0.680.386--−2.02−3.04, −1.01\<0.001\* AB vs. steroid--−1.19−2.41, 0.030.056--−1.39−2.48, −0.300.012\* PRP vs. AB--0.65−0.21, 1.510.138--−0.63−1.47, 0.200.138TreatmentWithin 2 monthsAt last follow-up*N*Mean95 % CI*P* value*N*Mean95 % CI*P* valueDASH PRP5146.1535.37, 56.93\<0.001\*6617.388.42, 26.33\<0.001\* AB307.49−7.61, 22.59\<0.001\*307.49−7.61, 22.59\<0.001\* Steroid7931.7622.81, 40.71\<0.001\*9435.9528.10, 43.80\<0.001\*TreatmentWithin 2 monthsAt last follow-up*N*Mean difference95 % CI*P* value*N*Mean difference95 % CI*P* valueDASH PRP vs. steroid--14.391.77, 27.000.025\*--−18.58−29.08, −8.080.001\* AB vs. steroid--−24.27−40.68, −7.860.004\*--−24.27−40.68, −7.860.004\* PRP vs. AB--38.6620.48, 56.83\<0.001\*--9.88−7.32, 27.080.260TreatmentWithin 2 monthsAt last follow-up*N*Mean95 % CI*P* value*N*Mean95 % CI*P* valuePRTEE PRP10036.3724.09, 48.66\<0.001\*10029.3117.03, 41.60\<0.001\* AB10034.1221.84, 46.41\<0.001\*10033.8721.59, 46.16\<0.001\* Steroid5030.8218.53, 43.11\<0.001\*5032.5320.24, 44.82\<0.001\*TreatmentWithin 2 monthsAt last follow-up*N*Mean difference95 % CI*P* value*N*Mean difference95 % CI*P* valuePRTEE PRP vs. steroid--5.55−6.65, 17.760.373--−3.22−15.42, 8.990.605 AB vs. steroid--3.30−8.90, 15.510.596--1.34−10.86, 13.550.829 PRP vs. AB--2.25−9.96, 14.460.718--−4.56−16.77, 7.650.464TreatmentWithin 2 monthsAt last follow-up*N*Mean95 % CI*P* value*N*Mean95 % CI*P* valuePPT PRP5818.5812.66, 24.51\<0.001\*5820.0314.11, 25.96\<0.001\* AB3021.2315.16, 27.31\<0.001\*3027.5321.46, 33.61\<0.001\* Steroid8817.5711.70, 23.44\<0.001\*8817.6711.80, 23.54\<0.001\*TreatmentWithin 2 monthsAt last follow-up*N*Mean difference95 % CI*P* value*N*Mean difference95 % CI*P* valuePPT PRP vs. steroid--1.02−0.48, 2.520.184--2.370.87, 3.870.02\* AB vs. steroid--3.671.64, 5.69\<0.001\*--9.877.84, 11.89\<0.001\* PRP vs. AB--−2.65−5.00, −0.30\<0.001--−7.50−9.85, −5.15\<0.001\*TreatmentWithin 2 monthsAt last follow-up*N*IR95 % CI*P* value*N*IR95 % CI*P* valueAdverse effects PRP--------850.100.03, 0.34\<0.001\* AB--------740.200.06, 0.650.008\* Steroid--------1290.110.03, 0.35\<0.001\*TreatmentWithin 2 monthsAt last follow-up*N*RR95 % CI*P* value*N*RR95 % CI*P* valueAdverse effects PRP vs. steroid----------0.900.36, 2.240.821 AB vs. steroid----------1.880.95, 3.720.068 PRP vs. AB----------0.0040.0002, 0.090.001\**PRP* platelet-rich plasma, *AB* autologous blood, *Steroid* corticosteroid, *VAS* visual analog score, *DASH* Disabilities of the Arm Shoulder and Hand, *PRTEE* Patient-Rated Tennis Elbow Evaluation, *PPT* pressure pain threshold, *CI* confidence interval, *IR* incident rate, *RR* relative risk**\*** Statistically significant difference (*P* \< 0.05)Fig. 2**a** Network meta-analysis of effects of treatment on VAS, **b** network meta-analysis of effects of treatment on DASH score, **c** network meta-analysis of effects of treatment on PPT, **d** network meta-analysis of effects of treatment on adverse effects

### Disabilities of the Arm Shoulder and Hand score {#Sec20}

Three studies \[[@CR12], [@CR19], [@CR21]\] were included in the network meta-analysis. After being adjusted for time frame, the regression analysis suggested that for assessment within 2 months, the mean difference in DASH score for AB injection was statistically significantly lower than for PRP and steroid injection, with a value of −38.66 (95 % CI −56.83, 20.48) and −24.27 (95 % CI −40.68, 7.86), respectively (Table [4](#Tab4){ref-type="table"}; Fig. [2](#Fig2){ref-type="fig"}b). However, assessment at the last follow-up of AB injection was statistically significantly lower than steroid injection but not significantly different when compared with PRP.

### Patient-Related Tennis Elbow Evaluation score {#Sec21}

Data from three studies \[[@CR5], [@CR14], [@CR26]\] were included in the network meta-analysis of PRTEE score (Table [4](#Tab4){ref-type="table"}). The lowest mean PRTEE scores were for steroid injection and PRP injection with a value of 30.82 (95 % CI 18.53, 43.11) and 29.31 (95 % CI 17.03, 41.60) when assessed within 2 months and at most recent follow-up, respectively. There was no significant difference between the two active treatments (Table [4](#Tab4){ref-type="table"}).

### Pressure pain threshold {#Sec22}

Data from three studies \[[@CR12], [@CR23], [@CR24]\] were included in the network meta-analysis of PPT (Table [4](#Tab4){ref-type="table"}). The highest mean PPT was for AB injection with a value of 21.23 (95 % CI 15.16, 27.31) and 27.53 (95 % CI 21.46, 33.61) when assessed within 2 months and at last follow-up, respectively. The regression analysis suggested that the mean difference in PPT for AB injection was statistically significantly higher than for PRP and steroid injection with a value of 2.65 (95 % CI 0.30, 5.00) and 3.67 (95 % CI 1.64, 5.69) when assessed within 2 months and at last follow-up assessment, respectively; the mean difference between PRP and AB was statistically significant and increased to 7.50 (95 % CI 5.15, 9.85) and 9.87 (95 % CI 7.84, 11.89) (Table [4](#Tab4){ref-type="table"}; Fig. [2](#Fig2){ref-type="fig"}c).

### Adverse effects (local pain and skin reaction) and non-response rates {#Sec23}

Data from five studies \[[@CR6], [@CR12], [@CR14], [@CR21], [@CR33]\] were included in the network meta-analysis. Compared to AB injection, PRP and steroid injection had lower risks of having complications, with borderline statistical significance of 99.6 % (RR = 0.004; 95 % CI 0.0002, 0.09) and 53 % (RR = 0.53; 95 % CI 0.27, 1.05), respectively. PRP injection had an approximately 10 % (RR = 0.90; 95 % CI 0.36, 1.27), statistically not significant, lower risk than steroid injection (Table [4](#Tab4){ref-type="table"}; Fig. [2](#Fig2){ref-type="fig"}d).

Discussion {#Sec24}
==========

The result of the present study was that PRP injection significantly improves pain and PRTEE score when compared with AB injection and steroid injection. Compared to AB injection, steroid injection had significantly improved disability score (DASH) and significantly improved pressure pain threshold (PPT). The chances of adverse effects from PRP injection and steroid injection were not significantly different but AB injection had a significantly higher chance of adverse effects when compared with steroid injection. Multiple active treatment comparisons with time adjustment indicated that within 2 months only AB injection showed an improvement of borderline significance (0.0056) in pain VAS, but PRP and AB injection showed a significant improvement in pain VAS when compared with steroid injections. AB injection had significantly improved DASH scores and PPT when compared with PRP and steroid injections, but AB injection had a statistically significantly higher risk of adverse effects when compared with PRP and steroid injections at the last follow-up assessment. For PRTEE score, there was no significant difference between the two active treatments.

The results of this study were consistent with previous meta-analyses by Ahmad et al. \[[@CR1]\] which showed that PRP was more efficacious than AB injection in terms of pain VAS, and that PRP was more efficacious than steroid injections in terms of pain VAS. There is additional evidence with good methodological quality (RCT) that PRP injection and AB injection displays an improvement in disability scores (DASH, PRTEE) and pressure pain threshold (PPT) when compared with steroid injection. However, the highest risk of having adverse effects was with AB injection when compared with PRP and steroid injections.

The direct meta-analysis suggests potential benefits of AB injection in reducing pain, improving disabilities scores and pressure pain threshold, but increasing the risk of adverse effects when compared with steroids, whereas PRP injection can reduce pain, improve disabilities scores and pressure pain threshold, but has increased rates of non-response after injection when compared with steroid injections. However, for other outcomes there was no significant difference. There are limitations of direct meta-analysis from the small number of studies that evaluated each particular pair of treatments, but a network meta-analysis circumvents this problem by creating indirect comparisons between active treatments and difference in time of assessment that can identify the most effective therapy and the time period that is the most beneficial. In this case, AB injection was the best therapy at the assessment times of within 2 months and over 2 months for improvement of DASH score and PPT, as during the second time period it had a cumulative effect. AB injection may be the worst therapy in terms of risks of adverse effects when compared with PRP and steroid injections. None of the RCTs compared combined treatments with AB injection or PRP injection and steroid injection.

This study has several strengths. A network meta-analysis was applied to increase the power of the tests and reduce Type I errors. A regression model was used, taking into account study effects in order to assess treatment effects. The network meta-analysis 'borrows' treatment information from other studies and increases the total sample size. As a result, treatment effects that could not be detected in direct meta-analysis could be identified. All possible treatment comparisons are mapped and displayed in Table [5](#Tab5){ref-type="table"}. Although the pooled estimates were heterogeneous, the regression model with cluster effect takes variations at the study level into account. The limitations recognized in this review are that some pooled results were heterogeneous but the source of heterogeneity was not explored due to limitations in the reported data.Table 5Summary of all treatment effects for lateral epicondylitis patientsTreatmentsPain VASDASH scorePRTEE scorePPTAdverse effectsNon-response ratePRP vs. AB(D\* & N)(N\*)(D\* & N)(D & N\*)(D & N\*)--PRP vs. steroid(D\* & N\*)(D\* & N\*)(D\* & N)(N\*)(D & N)(D\*)AB vs. steroid(D\* & N\*)(D\* & N\*)(D\* & N)(D\* & N\*)(D\* & N)--*D* direct, *N* network**\*** Statistically significant difference (*P* \< 0.05)

Based on the evidence presented, it can be concluded that when comparing three active treatments, PRP injection was the best treatment for reducing pain VAS after 2 months whereas AB injection was the best treatment for improving disabilities scores (DASH, PRTEE) and increasing pressure threshold (PPT) both within and after 2 months. However, AB injection had the highest risk of adverse effects (injection site pain and skin reaction). Further research should be done regarding cost-effective analysis comparing PRP injection and AB injection or the combination of AB injection and multi-modality physical therapy, possibly improving outcomes for pain, disabilities scores, and pressure pain threshold as well as lowering the risk of adverse effects.

In conclusion, this network meta-analysis has provided additional information that PRP injection or AB injection can be selected for management of chronic lateral epicondylitis. PRP can improve pain and lower the risk of adverse effects whereas AB injection can improve pain, disabilities scores and pressure pain threshold but has a higher risk of adverse effects.
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